Pancreatic Cancer Research

ResearcherUniversity of South AustraliaNo recent work listed

Ashleigh Hull

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3361-997X; OpenAlex author ID A5037271670. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
0
Labs led
0
Collaborators
3
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 2 papers

Papers 5

  1. In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer. Co-author DOI 10.1186/s41181-023-00204-4↗
  2. Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration. Co-author DOI 10.1186/s41181-023-00209-z↗
  3. Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells11192983↗
  4. Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature. Co-author DOI 10.3390/cancers12020481↗
  5. The Expression Profile and Textural Characteristics of C595-Reactive MUC1 in Pancreatic Ductal Adenocarcinoma for Targeted Radionuclide Therapy. Co-author DOI 10.3390/cancers13010061↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eva Bezak · 5 shared papers, 2020–2023 · strength 0.86
  2. Alexander H. Staudacher · 1 shared paper, 2022 · strength 0.16
  3. Barry Allen · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.